Phase 3 Myasthenia Gravis Trial, Recruiting NCT07249632 Sponsor: RemeGen Co., Ltd. Condition: Myasthenia Gravis
Back to Myasthenia Gravis

Phase 3 Myasthenia Gravis Trial, Recruiting

NCT07249632
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to sign a consent form agreeing to take part in the study.
  • You are between 12 and 80 years old (male or female).
  • You weigh at least 30 kg (about 66 pounds).
  • You have been diagnosed with Myasthenia Gravis (MG) with symptoms that match the disease.
  • Your MG has been classified as "Type I" by your doctor, using a specific medical grading system called the MGFA classification (confirm with trial site).
  • You are currently on a steady, unchanged treatment plan for your MG.

Who may not be able to join:

  • You have another autoimmune disease that requires you to take steroid medications (such as prednisone).
  • Your recent blood or lab test results show significant abnormalities (confirm with trial site).
  • You have used additional immune-suppressing medications — beyond your current stable MG treatment — in the past month.
  • You currently have an infection (either short-term or long-term) that needs treatment.
  • You have active hepatitis or a history of serious liver disease.
  • You have tested positive for HIV.
  • You have tested positive for syphilis.
  • You have poorly controlled diabetes, based on specific blood sugar test results (confirm with trial site).
  • You have a thymus gland tumor (thymoma) that falls into certain stages of severity (confirm with trial site).
  • You have another uncontrolled long-term illness, mental health condition, or neurological condition (other than MG) that could affect the study results.
  • You have another condition — not MG — that causes drooping eyelids, muscle weakness, or double vision (such as a thyroid eye disease or muscular dystrophy).
  • You have a known allergy to medicines or products made from human biological material.

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
RemeGen Co., Ltd.
Registry
ClinicalTrials.gov
Start date
13 January 2026
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change from baseline in the MGII (PRO) ocular score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov